| ［1］ |
Lu Q, Xu Y, Zhang Z, et al. Primary hypertrophic osteoarthropathy: genetics, clinical features and management［J/OL］. Front Endocrinol, 2023, 14: 1235040. DOI: 10.3389/fendo.2023.1235040.
|
| ［2］ |
Bloch A, Couture G, Isidor B, et al. Novel pathogenic variants in SLCO2A1 causing autosomal dominant primary hypertrophic osteoarthropathy［J/OL］. Eur J Med Genet, 2023, 66（2）: 104689. DOI: 10.1016/j.ejmg.2022.104689.
|
| ［3］ |
Lu Q, Xu Y, Li S, et al. Clinical and biochemical characteristics of 12 Chinese primary hypertrophic osteoarthropathy patients with HPGD mutations［J］. Int J Biol Sci, 2022, 18（9）: 3908－3917.
|
| ［4］ |
Tüysüz B, Yılmaz S, Kasapçopur Ö, et al. Primary hypertrophic osteoarthropathy caused by homozygous deletion in HPGD gene in a family: changing clinical and radiological findings with long-term follow-up［J］. Rheumatol Int, 2014, 34（11）: 1539－1544.
|
| ［5］ |
Wang Q, Li YH, Lin GL, et al. Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature［J/OL］. Orphanet J Rare Dis, 2019, 14（1）: 297. DOI: 10.1186/s13023－019－1264－5.
|
| ［6］ |
Umeno J, Esaki M, Hirano A, et al. Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease［J］. J Gastroenterol, 2018, 53（8）: 907－915.
|
| ［7］ |
Yousaf M, Khan R, Akram Z, et al. Primary hypertrophic osteoarthropathy with myelofibrosis［J/OL］. Cureus, 2022, 14（10）: e30108. DOI: 10.7759/cureus.30108.
|
| ［8］ |
Martínez-Lavín M, Pineda C, Navarro C, et al. Primary hypertrophic osteoarthropathy: Another heritable disorder associated with patent ductus arteriosus［J］. Pediatr Cardiol, 1993, 14（3）: 181－182.
|
| ［9］ |
Li S, Li Q, Wang Q, et al. Primary hypertrophic osteoarthropathy with myelofibrosis and anemia: a case report and review of literature［J］. Int J Clin Exp Med, 2015, 8（1）: 1467－1471.
|
| ［10］ |
Zhang Z, He JW, Fu WZ, et al. Mutations in the SLCO and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization［J］. J Clin Endocrinol Metab, 2013, 98（5）: E923－E933.
|
| ［11］ |
Samuel M, Rajamurugan A, Subramanian R, et al. Primary hypertrophic osteoarthropathy presenting as juvenile idiopathic arthritis: a case report［J/OL］. Int J Contemp Pediatr, 2025. DOI: 10.18203/2349－3291.ijcp20250361.
|
| ［12］ |
Shakya P, Pokhrel KN, Mlunde LB, et al. Effectiveness of non-steroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: a systematic review［J］. J Dermatol Sci, 2018, 90（1）: 21－26.
|
| ［13］ |
Albawa’neh A, Al Mansoori MG, Diab S, et al. Etoricoxib as a treatment of choice for patients with SLCO2A1mutation exhibiting autosomal recessive primary hypertrophic osteoarthropathy: a case report［J/OL］. Front Genet, 2022, 13: 1053999. DOI: 10.3389/fgene.2022.1053999.
|
| ［14］ |
Theodoridou A, Gika H, Diza E, et al. In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis［J］. Mediterr J Rheumatol, 2017, 28（1）: 33－40.
|
| ［15］ |
De Vecchis R, Baldi C, Di Biase G, et al. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen［J］. Minerva Cardioangiol, 2014, 62（6）: 437－448.
|
| ［16］ |
Schmidt M, Sørensen HT, Pedersen L. Cardiovascular risks of diclofenac versus other older COX-2 inhibitors（meloxicam and etodolac）and newer COX-2 inhibitors（celecoxib and etoricoxib）: a series of nationwide emulated trials［J］. Drug Saf, 2022, 45（9）: 983－994.
|
| ［17］ |
Li SS, He J-W, Fu WZ, et al. Clinical, biochemical, and genetic features of 41 Han Chinese families with primary hypertrophic osteoarthropathy, and their therapeutic response to etoricoxib: results from a six-month prospective clinical intervention［J］. J Bone Miner Res, 2017, 32（8）: 1659－1666.
|
| ［18］ |
Sun F, Guo L, Ye S. Primary hypertrophic osteoarthropathy with SLCO2A1 mutation in a Chinese patient successfully treated with etoricoxib［J］. J Clin Rheumatol, 2018, 24（3）: 164－167.
|
| ［19］ |
Ahmad Ganai S, Rajamanikandan S, Shah BA, et al. Comparative structural study of selective and non-selective NSAIDs against the enzyme cyclooxygenase-2 through real-time molecular dynamics linked to post-dynamics MM-GBSA and e-pharmacophores mapping［J/OL］. J Mol Model, 2023, 29（6）: 192. DOI: 10.1007/s00894－023－05603－7.
|
| ［20］ |
Yuan L, Liao RX, Lin YY, et al. Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: a single-arm intervention trial［J］. J Orthop Transl, 2019, 18: 109－118.
|
| ［21］ |
廖若西. 原发性肥大性骨关节病Wnt通路相关因子水平和COX-2抑制剂干预后的变化［D］. 北京: 北京协和医学院, 2015.
|
| ［22］ |
Xu Y, Zhang Z, Yue H, et al. Monoallelic mutations in SLCO2A1 cause autosomal dominant primary hypertrophic osteoarthropathy［J］. J Bone Miner Res, 2021, 36（8）: 1459－1468.
|
| ［23］ |
黄妙清. 原发性肥大性骨关节病家系遗传学研究及依托考昔治疗效果观察［D］. 广州: 南方医科大学, 2018.
|
| ［24］ |
Huang S, Yan Y, Su F, et al. Research progress in gene editing technology［J/OL］. Front Biosci（Landmark Ed）, 2021, 26（10）: 916. DOI: 10.52586/4997.
|
| ［25］ |
Xie Y. Research progress in gene editing technologies and their applications in aging-related genes［J］. J Food Sci Nutr Health, 2025, 4（1）: 82－89.
|